China Universal Asset Management Co., Ltd. Kymera Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$773 Million
Q1 2024

A detailed history of China Universal Asset Management Co., Ltd. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,753 shares of KYMR stock, worth $355,528. This represents 0.06% of its overall portfolio holdings.

Number of Shares

11,753

Previous 11,753 -0.0%

Holding current value

$355,528

Previous $472,000 -0.0%

% of portfolio

0.06%

Previous 0.06%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$22.9 - $43.57 $122,056 - $232,228	5,330 Added 82.98%	11,753 $472,000
Q4 2023 May 21, 2024	SELL	$10.97 - $26.84 $58,470 - $143,057	-5,330 Reduced 45.35%	6,423 $163,000
Q4 2023 Jan 23, 2024	BUY	$10.97 - $26.84 $54,871 - $134,253	5,002 Added 352.01%	6,423 $164,000
Q3 2023 May 21, 2024	BUY	$13.9 - $23.88 $9,674 - $16,620	696 Added 96.0%	1,421 $19,000
Q3 2023 Oct 30, 2023	BUY	$13.9 - $23.88 $9,674 - $16,620	696 Added 96.0%	1,421 $20,000

Q2 2023 May 21, 2024	SELL	$22.4 - $34.92 $515 - $803	-23 Reduced 3.07%	725 $16,000
Q2 2023 Jul 27, 2023	SELL	$22.4 - $34.92 $515 - $803	-23 Reduced 3.07%	725 $17,000
Q1 2023 May 21, 2024	BUY	$24.84 - $38.75 $4,744 - $7,401	191 Added 34.29%	748 $22,000
Q1 2023 Apr 27, 2023	BUY	$24.84 - $38.75 $4,744 - $7,401	191 Added 34.29%	748 $22,000
Q4 2022 May 21, 2024	SELL	$19.57 - $30.92 $219,105 - $346,180	-11,196 Reduced 95.26%	557 $13,000
Q4 2022 Jan 31, 2023	BUY	$19.57 - $30.92 $1,409 - $2,226	72 Added 14.85%	557 $14,000
Q3 2022 Oct 21, 2022	BUY	$20.91 - $34.27 $10,141 - $16,620	485 New	485 $11,000

Others Institutions Holding KYMR

# of Institutions

164

Shares Held

63.1M

Call Options Held

39.7K

Put Options Held

9.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $1.65B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account

China Universal Asset Management Co., Ltd. Kymera Therapeutics, Inc. Transaction History